Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pulse Biosciences announced positive interim results from its PRECISE-BTN study, which assesses the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules. The findings were shared at the 95th Annual Meeting of the American Thyroid Association. This multicenter study aims to address symptomatic and hyperfunctioning thyroid nodules.

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim results show promising outcomes.
  • Study evaluates innovative nano-PFA technology.
  • Research presented at a prestigious annual meeting.

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs). The results were presented at the 95th Annual Meet

Frequently Asked Questions

What is the PRECISE-BTN study?

It is a multicenter study evaluating the nPulse Vybrance system for thyroid nodules.

What technology does Pulse Biosciences use?

They leverage Nanosecond Pulsed Field Ablation technology.

Where were the results presented?

The results were presented at the American Thyroid Association Annual Meeting.

What type of nodules does the study focus on?

The study focuses on symptomatic and hyperfunctioning benign thyroid nodules.

ShareAdd on Google
Tags: PLSE Pulse Biosciences benign thyroid nodules nano-PFA nPulse Vybrance ATA meeting
Last updated: Nov 6, 2026

Biotech snapshot

Cash runway
$189M liquidity · $5M/mo burn
~37 mo
Minimal dilution risk